<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162799</url>
  </required_header>
  <id_info>
    <org_study_id>ICO5TRI/2/01</org_study_id>
    <nct_id>NCT00162799</nct_id>
  </id_info>
  <brief_title>Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity</brief_title>
  <official_title>Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J. Uriach and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>J. Uriach and Company</source>
  <brief_summary>
    <textblock>
      To explore the efficacy of triflusal in the attenuation of insulin resistance in human
      obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic
      agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced
      insulin resistance by triflusal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal,
      placebo-controlled.

      Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days
      placebo, 15 days

      Washout period: 30 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction antropometric measures associated with insulin resistance and arterial hypertension.</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Insulin Resistance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triflusal (DCI)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 35 to 60 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Manuel Fernández del Real, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad Diabetología. Serv Endocrino Hosp Josep Trueta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>June 22, 2006</last_update_submitted>
  <last_update_submitted_qc>June 22, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2006</last_update_posted>
  <keyword>insulin resistance and inflamation</keyword>
  <keyword>insulin sensitibity</keyword>
  <keyword>obesity-induced insuline resistence</keyword>
  <keyword>obesity-diabetes link</keyword>
  <keyword>salicylate</keyword>
  <keyword>insulin resistance in obesity health adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Triflusal</mesh_term>
    <mesh_term>Salicylates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

